title: Genetically engineered myeloma cell vaccine.
abstract: Tumor cells engineered to express immunogenes have been used for cancer vaccines to induce antitumor immunity and to study the antitumor immune mechanisms derived from immunogene expression. In this chapter, we describe the design and methods for cloning a cDNA gene coding for the mouse CD40L molecule and for construction of the expression vector pcDNA-CD40L, as well as the methods for generation of engineered myeloma cells J558/CD40L expressing CD40 ligand. We also demonstrate that the engineered J558/CD40L tumor cells lose their tumorigenicity in syngeneic mice, and that the inoculation of J558/CD40L tumor cells further leads to protective immunity against wild-type J558 tumors.
authors.affiliation: Sakatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada.
authors.forename: Siguo
authors.initials: S
authors.lastname: Hao
authors.forename: Tim
authors.initials: T
authors.lastname: Chan
authors.forename: Jim
authors.initials: J
authors.lastname: Xiang
mesh_terms: D000818:Animals; D023201:CD40 Ligand / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines; D003001:Cloning, Molecular; D018076:DNA, Complementary / Q000235:genetics; D004195:Disease Models, Animal; D005818:Genetic Engineering / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D018076:DNA, Complementary; D023201:CD40 Ligand